- INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 15, 2026 · gurufocus.com
INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit P
- INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 15, 2026 · prnewswire.com
SAN DIEGO, May 15, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period"), have until Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
- INVESTOR NOTICE: MEDPACE HOLDINGS INC. (MEDP) INVESTORS WITH SUBSTANTIAL LOSSES HAVE OPPORTUNITY TO LEAD CLASS ACTION LAWSUIT
May 15, 2026
SAN DIEGO, MAY 15, 2026 /PRNEWSWIRE/ -- ROBBINS GELLER RUDMAN & DOWD LLP ANNOUNCES THAT PURCHASERS OR ACQUIRERS OF MEDPACE HOLDINGS INC. (NASDAQ: MEDP) COMMON STOCK BETWEEN APRIL 22, 2025 AND FEBRUARY 9, 2026, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), HAVE UNTIL MONDAY, JUNE 8, 2026 TO SEEK APPOINTMENT AS LEAD PLAINTIFF OF THE MEDPACE CLASS ACTION LAWSUIT. CAPTIONED DURBIN V.
- Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
May 15, 2026
LOS ANGELES, May 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 8, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).
IF YOU SUFFERED A LOSS ON YOUR MEDPACE INVESTMENTS, CLICK HERETO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
What Happened?
On February 9, 2026, Medpace released its fourth quarter 2025 financial results, revealing a book-to-bill ratio of 1.04, well below the Company’s guidance of 1.15. The Company attributed the miss to backlog cancellations being “the highest they’ve been in over a year.”
On this news, Medpace’s stock price fell $84.30, or 15.9%, to close at $446.05 per share on February 10, 2026, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) consistently oversold the Company's projected book-to-bill ratio for fourth quarter 2025; (2) knew or recklessly disregarded the impact that cancellations have on the Company's book-to-bill ratio; (3) frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (4) reassured investors that the Company was not concerned about the lack of diversity in its pre-backlog; (5) stated that, despite the uptick in metabolic growth, the Company's upside was broad-based and not isolated to any handful of studies; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Medpace common stock during the Class Period, you may move the Court no later than June 8, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
- Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
May 15, 2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/MEDP.
Medpace Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
(1) Medpace’s public statements regarding its expected book-to-bill ratio for the fourth quarter and second half of fiscal year 2025 lacked a reasonable basis;
(2) Defendants repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information; and
(3) as a result, Defendants’ statements about the Company’s business, operations, and financial prospects were materially false and misleading at all relevant times.
What's Next for Medpace Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/MEDP. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Medpace you have until June 5, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Medpace Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Medpace Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
- Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
May 15, 2026 · globenewswire.com
LOS ANGELES, May 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 8, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).
- DEADLINE ALERT: MEDPACE HOLDINGS, INC. (MEDP) SHAREHOLDERS WHO LOST MONEY URGED TO CONTACT GLANCY PRONGAY WOLKE & ROTTER LLP ABOUT SECURITIES FRAUD LAWSUIT
May 15, 2026
LOS ANGELES, MAY 15, 2026 (GLOBE NEWSWIRE) -- GLANCY PRONGAY WOLKE & ROTTER LLP REMINDS INVESTORS OF THE UPCOMING JUNE 8, 2026 DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN THE CLASS ACTION FILED ON BEHALF OF INVESTORS WHO PURCHASED OR OTHERWISE ACQUIRED MEDPACE HOLDINGS, INC. (“MEDPACE” OR THE “COMPANY”) (NASDAQ: MEDP) COMMON STOCK BETWEEN APRIL 22, 2025 AND FEBRUARY 9, 2026, INCLUSIVE (THE “CLASS PERIOD”).
- Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
May 15, 2026 · globenewswire.com
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”).
- BRONSTEIN, GEWIRTZ & GROSSMAN LLC URGES MEDPACE HOLDINGS, INC. INVESTORS TO ACT: CLASS ACTION FILED ALLEGING INVESTOR HARM
May 15, 2026
NEW YORK, MAY 15, 2026 (GLOBE NEWSWIRE) -- BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, A NATIONALLY RECOGNIZED INVESTOR-RIGHTS LAW FIRM, ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST MEDPACE HOLDINGS, INC. (NASDAQ: MEDP) AND CERTAIN OF ITS OFFICERS. THIS LAWSUIT SEEKS TO RECOVER DAMAGES AGAINST DEFENDANTS FOR ALLEGED VIOLATIONS OF THE FEDERAL SECURITIES LAWS ON BEHALF OF ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED MEDPACE SECURITIES BETWEEN APRIL 22, 2025 AND FEBRUARY 9, 2026, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”).
- Medpace Class Actions Put Backlog Disclosures And Governance In Spotlight
May 15, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Multiple securities fraud class action lawsuits have been filed against Medpace Holdings, Inc. (NasdaqGS:MEDP) over alleged misstatements about backlog cancellation rates and business prospects. Law firms are encouraging shareholders who purchased Medpace securities during the relevant periods to consider joining these actions. The suits follow fourth quarter results that plaintiffs claim conflicted with earlier comments about Medpace’s backlog quality and outlook.
Medpace, a contract research organization with a recent share price of $419.17, has seen mixed share performance, with the stock up 41.4% over the past year but down 19.4% over the past month and down 26.6% year to date. The new legal actions focus on how the company communicated key operating metrics, which are closely watched by investors given Medpace’s history of substantial multi year returns.
For current and potential shareholders, the lawsuits raise questions less about short term price moves and more about disclosure practices and governance. As the cases progress, investors will be watching for additional information from both the company and the courts that could clarify the underlying claims, any potential financial exposure, and how Medpace approaches communication of its backlog and growth outlook going forward.
Stay updated on the most important news stories for Medpace Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Medpace Holdings.NasdaqGS:MEDP 1-Year Stock Price Chart
Is Medpace Holdings's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.
The core issue in these class actions is not Medpace’s recent trading volatility, but whether investors had an accurate picture of key operating metrics such as book to bill and backlog cancellations before the weaker Q4 2025 figures and subsequent share price drops. If courts find that disclosures were incomplete or misleading, Medpace could face financial penalties, settlement costs, and tighter oversight of how it reports contract metrics that help investors gauge future revenue. The resignation of the president and the later Q1 update, where the company reported revenue growth yet the stock still declined 16.6% after the print, underline how sensitive the market is to any perceived gap between commentary and reported numbers. Compared with other contract research organizations like IQVIA, ICON, and Labcorp, investor confidence in Medpace’s disclosures will be central, because backlog quality and cancellations are critical for judging earnings visibility.
Story Continues
How This Fits Into The Medpace Holdings Narrative
The focus on cancellations and book to bill directly ties into earlier concerns that growth depended on low cancellations and a particular mix of faster burning contracts. The lawsuits challenge the idea that Medpace’s backlog and bookings provided clear visibility, especially where the narrative pointed to strong demand and backlog resilience. Potential governance and disclosure scrutiny in court is not fully reflected in prior narratives that emphasized operational execution and contract efficiency.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Medpace Holdings to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Legal outcomes could lead to settlement costs, higher compliance expenses, or changes in how Medpace communicates key metrics like book to bill and cancellations. ⚠️ Reputational questions around disclosure quality may weigh on how investors view management credibility, especially if further cancellations or backlog shifts appear. 🎁 The lawsuits may prompt clearer disclosure standards for backlog, client concentration, and cancellations, giving investors better tools to assess future revenue visibility. 🎁 Despite the legal overhang, Medpace continues to operate in a sector with broad clinical trial demand, alongside peers such as IQVIA and ICON, which may support contract wins over time.
What To Watch Going Forward
Investors should track key court milestones, any company updates on internal reviews, and whether Medpace changes how it reports backlog, book to bill, or client concentration. Commentary around the president’s planned resignation and future leadership structure will matter for confidence in governance. It is also worth watching how new bookings and cancellations trend in upcoming quarters and whether further guidance on revenue mix is provided to clarify how much comes from faster burning or pass through heavy work.
To stay updated on how the latest news impacts the investment narrative for Medpace Holdings, head to the community page for Medpace Holdings to follow the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MEDP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
